Clinical-stage biopharmaceutical company IO Biotech has announced the appointment of Kathleen Glaub to its board of directors.
“Ms. Glaub has outstanding experience and a strong track record in strategic decision making and creating value in companies. We look forward to continuing to develop our company under her guidance,” said IO Biotech CEO Mai-Britt Zocca.
Before joining IO Biotech to assist in its aim of developing immune modulating anti-cancer therapies, Glaub held positions at Afferent Pharmaceuticals, Cell Genesys, Genetech, and Intel Corporation. She had also been a strategic advisor to IO Biotech since September 2017.
Glaub is a graduate of Northwestern University, Illinois, and the University of California, Berkeley.